A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
ApexOnco Front Page
Recent articles
Persevera is a bust, but Roche hasn’t given up on the front line.
Global phase 2 data in TNBC look similar to earlier results in China.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
The company might have blown Enliven out of the water.
Pfizer reveals the discontinuation of PF-08046044.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Studies presented at ASH show this to be true only up to a point.
